Cell-based therapies provide a novel approach to treating chronic diseases. Recapitulating a damaged organ's function by secreting hormones or other factors is dependent upon successful engraftment of transplanted cells. Engraftment of the transplanted cells requires that cells survive the initial hypoxic environment following transplantation, connect with the host vasculature for exchange of nutrients and waste products and also deliver secreted factors into the circulation. Doing this requires creating an environment that promotes long term function of the transplanted cells. If the cell supply is limited, approaches to expand the transplant graft in vivo may also be important. We propose to address the hypothesis that micro-porous polymer scaffolds capable of delivering biologically active peptides can create a microenvironment to promote cell engraftment, survival and proliferation. A classic paradigm for cell-based therapy is islet transplantation for treatment of type 1 diabetes in which destruction of insulin-secreting beta cells in the pancreas results in hyperglycemia and its complications. Recent trials have provided proof of concept that islet transplantation can be efficacious, yet problems remain. To address these problems, we are proposing to transplant islets on microporous scaffolds capable of releasing proteins that can influence the host tissue (e.g., vascularization) or enhance the functionality of the transplanted islets. These factors will condition the microenvironment to promote islet engraftment, survival, and function. We have recently shown that microporous scaffolds can serve as a platform for islet transplantation.
The Specific Aims are as follows. (i) 1) To investigate the hypothesis that the scaffold architecture, as defined by porosity, pore size, and stability, will influence islet engraftment and function. (ii) To address the hypothesis that use of a polymer scaffold to deliver angiogenic factors will improve islet survival and function post-transplantation in a murine model of diabetes. (iii) To test the hypothesis that polymer scaffolds delivering factors that inhibit islet cell death and/or increase islet cell mass post-transplantation will enhance islet engraftment and function. (iv) To determine whether delivering a combination of growth factors that affect different processes (e.g., angiogenesis and islet cell survival and/or proliferation) is more efficacious than delivering a single factor. These studies have the potential to substantially advance cell therapies for islet transplantation.
Transplantation of islets or, ultimately, insulin-secreting cells from other sources represents a potential cure for diabetes, which results from destruction of insulin-secreting cells by the immune system. To enhance cell replacement therapy for diabetes, we are developing scaffolds for transplantation of islets or insulin-secreting cells into peritoneal fat. These scaffolds provide a support for cell growth and can deliver proteins which will be to enhance cell survival and function following islet transplantation.
|Luo, Xunrong; Miller, Stephen D; Shea, Lonnie D (2016) Immune Tolerance for Autoimmune Disease and Cell Transplantation. Annu Rev Biomed Eng 18:181-205|
|Dumont, Courtney M; Margul, Daniel J; Shea, Lonnie D (2016) Tissue Engineering Approaches to Modulate the Inflammatory Milieu following Spinal Cord Injury. Cells Tissues Organs 202:52-66|
|Hlavaty, Kelan A; McCarthy, Derrick P; Saito, Eiji et al. (2016) Tolerance induction using nanoparticles bearing HY peptides in bone marrow transplantation. Biomaterials 76:1-10|
|Rao, Shreyas S; Bushnell, Grace G; Azarin, Samira M et al. (2016) Enhanced Survival with Implantable Scaffolds That Capture Metastatic Breast Cancer Cells In Vivo. Cancer Res 76:5209-18|
|Liu, Jeffrey M H; Zhang, Jesse; Zhang, Xiaomin et al. (2016) Transforming growth factor-beta 1 delivery from microporous scaffolds decreases inflammation post-implant and enhances function of transplanted islets. Biomaterials 80:11-9|
|Azarin, Samira M; Yi, Ji; Gower, Robert M et al. (2015) In vivo capture and label-free detection of early metastatic cells. Nat Commun 6:8094|
|Dumont, Courtney M; Park, Jonghyuck; Shea, Lonnie D (2015) Controlled release strategies for modulating immune responses to promote tissue regeneration. J Control Release 219:155-66|
|Hlavaty, Kelan A; Luo, Xunrong; Shea, Lonnie D et al. (2015) Cellular and molecular targeting for nanotherapeutics in transplantation tolerance. Clin Immunol 160:14-23|
|Bryant, Jane; Hlavaty, Kelan A; Zhang, Xiaomin et al. (2014) Nanoparticle delivery of donor antigens for transplant tolerance in allogeneic islet transplantation. Biomaterials 35:8887-94|
|Hlavaty, K A; Gibly, R F; Zhang, X et al. (2014) Enhancing human islet transplantation by localized release of trophic factors from PLG scaffolds. Am J Transplant 14:1523-32|
Showing the most recent 10 out of 20 publications